31 phenotypes from 3 alleles in 4 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Nhlrc1tm1(KOMP)Vlcg/Nhlrc1tm1(KOMP)Vlcg involves: C57BL/6J * C57BL/6NTac	abnormal astrocyte morphology	J:218959
	abnormal brain morphology	J:216806, J:218959
	abnormal excitatory postsynaptic potential	J:218959
	abnormal glial cell morphology	J:218959
	abnormal neuron morphology	J:218959
	decreased anxiety-related response	J:218959
	enhanced long-term potentiation	J:218959
	gliosis	J:218959
	hippocampal neuron degeneration	J:218959
	hyperactivity	J:218959
	increased brain glycogen level	J:165994
	increased cardiac muscle glycogen level	J:165994
	increased glycogen level	J:165994
	increased skeletal muscle glycogen level	J:165994, J:218959
	increased susceptibility to pharmacologically induced seizures	J:218959
	Lafora bodies	J:165994, J:218959
Nhlrc1tm1(KOMP)Vlcg/Nhlrc1tm1(KOMP)Vlcg involves: C57BL/6NTac	abnormal seizure response to electrical stimulation	J:210491
	abnormal seizure response to pharmacological agent	J:210491
	impaired autophagy	J:210491
	neuron degeneration	J:210491
Nhlrc1tm1.2Geno/Nhlrc1tm1.2Geno involves: 129S2/SvPas * C57BL/6J	abnormal autophagy	J:181559
	abnormal brain interneuron morphology	J:181559
	abnormal motor capabilities/coordination/movement	J:181559
	abnormal object recognition memory	J:181559
	abnormal spike wave discharge	J:181559
	Lafora bodies	J:181559
	limb grasping	J:181559
	lipofuscinosis	J:181559
	myoclonus	J:181559
Nhlrc1tm1Bmin/Nhlrc1tm1Bmin involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr	decreased glycogen catabolism rate	J:181674
	normal homeostasis/metabolism phenotype	J:181674
	increased liver glycogen level	J:181674
	increased skeletal muscle glycogen level	J:181674
	Lafora bodies	J:181674